

## Statement on the effectiveness of nucleic acid test kits for the SARS-CoV-2 variants detection

In response to the recent updated multiple variants of the novel coronavirus, our bioinformaticians have re-analyzed the alignment results of the detection target regions of our SARS-CoV-2 Nucleic Acid Diagnostic Kits (PCR-Fluorescence Probing) (No. S3122E, S3123E, S3124E) (NMPA Registration Number 20203400064), and also verified through wet experiment using Lentivirus particles. The variants include but not limited to the novel coronavirus variants such as Alpha (B.1.1.7), Beta (B.1.351/B.1.351.2/B.1.351.3), Gamma (P.1/P.1.1/P.1.2), Delta (B.1.617.2/AY.1/AY.2/AY.3) which have been labeled as "VOC of concern" by the World Health Organization (WHO), and the WHO VOI-labeled variants Eta (B.1.525), Iota (B.1.526), Kappa (B.1.617.1), Lambda (C.37), and the variants B.1.1.318, B.1.616, A.23.1, Epsilon (B.1.427/B.1.429), B.1.375, N.9, B.1, A.27, B.1.618, etc. All in silico and wet test results show that our kit can detect all reported variants accurately and didn't show any false-negative results or off-target situation for the above reported variants. We will continue to track and update the latest viral information including mutations and substitutions for SARS-CoV-2 to maintain the specificity and sensitivity of our products.

